An in vitro tool to assess cytochrome p450 drug biotransformation-dependent cytotoxicity in engineered hepg2 cells generated by using adenoviral vectors

Toxicology in Vitro

Volumn 27, Issue 4, 2013, Pages 1410-1415

  Lahoz, Agustín ^a   Vilà, Maya R ^b,e   Fabre, Myriam ^b   Miquel, Josep M ^b,e   Rivas, Manuel ^b,e   Maines, Jessica ^b   Castell, José V ^a,c,d   Gómez Lechón, M José ^a,c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b Advancell   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

^e LEITAT TECHNOLOGICAL CENTER   (Spain)

Author keywords

Adenovirus technology; Bioactivation mediated toxicity; Competent cells; Cytochrome P450; HepG2 cell line

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOVIRUS VECTOR; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4;

ARTICLE; CELL ENGINEERING; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOCHROME P450 1A2 GENE; CYTOCHROME P450 2A6 GENE; CYTOCHROME P450 2E1 GENE; CYTOCHROME P450 3A4 GENE; DRUG CYTOTOXICITY; DRUG TRANSFORMATION; ENZYME ACTIVITY; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; TRANSIENT EXPRESSION; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

ADENOVIRIDAE; BIOTRANSFORMATION; CELL SURVIVAL; CYTOCHROME P-450 ENZYME SYSTEM; GENETIC VECTORS; HEP G2 CELLS; HUMANS; PHARMACEUTICAL PREPARATIONS; TOXICITY TESTS, ACUTE; TRANSDUCTION, GENETIC;

ADENOVIRIDAE;

EID: 84876732322     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2012.08.001     Document Type: Article

References (32)

1. Aoyama K., Yoshinari K., Kim H.J., Nagata K., Yamazoe Y. Simultaneous expression of plural forms of human cytochrome P450 at desired ratios in HepG2 cells: adenovirus-mediated tool for cytochrome P450 reconstitution. Drug Metab. Pharmacokinet. 2009, 24:209-217.
2. Becker T.C., Noel R.J., Coats W.S., Gomez-Foix A.M., Alam T., Gerard R.D., Newgard C.B. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 1994, 43(Pt A):161-189.
3. Bai J., Cederbaum A.I. Adenovirus mediated overexpression of CYP2E1 increases sensitivity of HepG2 cells to acetaminophen induced cytotoxicity. Mol. Cell. Biochem. 2004, 262:165-176.
4. Bort R., Mace K., Boobis A., Gómez-Lechón M.J., Pfeifer A., Castell J.V. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathway. Biochem. Pharmacol. 1999, 58:787-796.
5. Carrière V., Berthou F., Baird S., Belloc C., Beaune P., de Waziers I. Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics 1996, 6:203-211.
6. Castell J.V., Hernández D., Gómez-Foix A.M., Guillén I., Donato M.T., Gómez-Lechón M.J. Adenovirus-mediated gene transfer into human hepatocytes: analysis of the biochemical functionality of transduced cells. Gene Ther. 1997, 4:455-464.
7. Donato M.T., Hallifax D., Picazo L., Castell J.V., Houston J.B., Gómez-Lechón M.J., Lahoz A. Metabolite formation kinetics and intrinsic clearance of phenacetin, tolbutamide, alprazolam, and midazolam in adenoviral cytochrome P450-transfected HepG2 cells and comparison with hepatocytes and in vivo. Drug Metab. Dispos. 2010, 38:1449-1455.
8. Gómez-Foix A.M., Coats W.S., Baqué S., Alam T., Gerard R.D., Newgard C.B. Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. J. Biol. Chem. 1992, 267:129-134.
9. Gómez-Lechón M.J., Castell J.V., Donato M.T. An update on metabolism studies using human hepatocytes in primary culture. Expert Opin. Drug Metab. Toxicol. 2008, 4:837-854.
10. Gómez-Lechón M.J., Lahoz A., Gombau L., Castell J.V., Donato M.T. In vitro evaluation of potential hepatotoxicity induced by drugs. Curr. Pharm. Des. 2010, 16:1963-1977.
11. Gorski J.C., Hall S.D., Jones D.R., VandenBranden M., Wrighton S.A. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 1994, 47:1643-1653.
12. Hosomi H., Akai S., Minami K., Yoshidawa Y., Fukami T., Nakajima M., Yokoi T. An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells. Toxicol. In Vitro 2010, 24:1032-1038.
13. Jover R., Hoffmann K., Meyer U.A. Induction of 5-aminolevulinate synthase by drugs is independent of increased apocytochrome P450 synthesis. Biochem. Biophys. Res. Commun. 1996, 226:152-157.
14. Lahoz A., Donato M.T., Picazo L., Gómez-Lechón M.J., Castell J.V. Determination of major human cytochrome P450s activities in 96-well plates using liquid chromatography tandem mass spectrometry. Toxicol. In Vitro 2007, 21:1247-1252.
15. Lahoz A., Donato M.T., Gómez-Lechón M.J., Castell J.V. Strategies to in vitro assessment of major human CYP enzyme activities by using liquid chromatography tandem mass spectrometry. Curr. Drug Metab. 2008, 9:12-19.
16. Lammert C., Bjornsson E., Niklasson A., Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010, 51:615-620.
17. Li A.P. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the " multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem. Biol. Interact. 2002, 142:7-23.
18. Li A.P. Evaluation of metabolism-based drug toxicity in drug development. Chem. Biol. Interact. 2009, 179:1-3.
19. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
20. Mace K., Offord E.A., Pfeifer A.M.A. Drug metabolism and carcinogen activation studies with human genetically engineered cells. In vitro Methods in Pharmaceutical Research 1996, 443-456. Academic Press, London. J.V. Castell, M.J. Gómez-Lechón (Eds.).
21. McCrory W.J., Bautista D.S., Graham F.L. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 1988, 163:614-617.
22. Raucy J.L., Lasker J.M., Lieber C.S., Black M. Acetaminophen activation by human liver cytochromes P450IIEI and P450IA2. Arch. Biochem. Biophys. 1989, 271:270-283.
23. Rodríguez-Antona C., Donato M.T., Boobis A., Edwards R.J., Watts P.S., Castell J.V., Gómez-Lechón M.J. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002, 32:505-520.
24. Sladek N.E. Metabolism of oxazaphosphorines. Pharmacol. Ther. 1988, 37:301-355.
25. Tang W., Lu A.Y.H. Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective. Drug Metab. Rev. 2010, 42:225-249.
26. Tassaneeyakul W., Birkett D.J., Veronese M.E., McManus M.E., Tukey R.H., Quattrochi L.C., Gelboin H.V., Miners J.O. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 1993, 265:401-407.
27. Uetrecht J.P. New concepts in immunology relevant to idiosyncratic drug reactions: the " danger hypothesis" and innate immune system. Chem. Res. Toxicol. 1999, 12:387-395.
28. Vignati L., Turlizzi E., Monaci S., Grossi P., Kanter R., Monshouwer M. An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology 2005, 216:154-167.
29. Yamazaky H., Tanaka M., Shimada T. Hyghly sensitive high-performance liquid chromatographic assay for coumarin 7-hydroxylation and 7-ethoxycoumarin O-deethylation by human liver cytochrome P450 enzymes. J. Chromatogr. B Biomed. Sci. Appl. 1999, 721:13-19.
30. Yoshitomi S., Ikemoto K., Takahashi J., Miki H., Namba M., Asahi S. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their application on drug metabolism and toxicology. Toxicol. In Vitro 2001, 15:245-256.
31. Wickham T.J. Targeting adenovirus. Gene Ther. 2000, 7:110-114.
32. Zhou S., Chan E., Duan W., Huang M., Chen Y.Z. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab. Rev. 2005, 37:41-213.